Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1160

—

c8b53963-adfa-59e3-a5a5-35f695945fde

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.402
  • TNFA_SIGNALING_VIA_NFKB+0.374
  • HYPOXIA+0.317
  • FATTY_ACID_METABOLISM+0.264
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.253
  • HEME_METABOLISM+0.248
  • COAGULATION+0.244
  • IL6_JAK_STAT3_SIGNALING+0.244
  • XENOBIOTIC_METABOLISM+0.235
  • INFLAMMATORY_RESPONSE+0.222

Top 10 suppressed

  • G2M_CHECKPOINT-0.347
  • MITOTIC_SPINDLE-0.339
  • E2F_TARGETS-0.314
  • TGF_BETA_SIGNALING-0.303
  • WNT_BETA_CATENIN_SIGNALING-0.300
  • HEDGEHOG_SIGNALING-0.297
  • NOTCH_SIGNALING-0.291
  • UV_RESPONSE_DN-0.249
  • ANDROGEN_RESPONSE-0.219
  • PROTEIN_SECRETION-0.171

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR2016959
head-neck@1
——0.768
2TCGA-49-4506-01A-01R-1206-07
lung-landscapes@6
—cohortA40.761
3TCGA-OL-A66P-01A-11R-A31O-07
breast-umap@18
—B0.744
4MNG956
mng-umap@100
——0.739
5SRR9879283
lung-landscapes@6
—cohortA10.737
6MDT-AP-2299
medullo-epn-umap@date-based
MedMedulloblastoma0.726
7TCGA-21-5784-01A-01R-1635-07
lung-landscapes@6
—cohortSQ10.717
8TCGA-64-1676-01A-01R-0946-07
lung-landscapes@6
—cohortA10.714
9MNG1165
mng-umap@100
——0.712
10TCGA-E9-A6HE-01A-11R-A31O-07
breast-umap@18
—B0.706

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.402Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.374Inavolisib— uncovered
HYPOXIA0.317Idelalisib— uncovered
FATTY_ACID_METABOLISM0.264Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.253Inavolisib— uncovered
HEME_METABOLISM0.248Temsirolimus— uncovered
COAGULATION0.244Binimetinib— uncovered
IL6_JAK_STAT3_SIGNALING0.244Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.235Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.222Idelalisib— uncovered
P53_PATHWAY0.194Idelalisib— uncovered
UV_RESPONSE_UP0.179Idelalisib— uncovered
MYC_TARGETS_V10.168Inavolisib— uncovered
ANGIOGENESIS0.164Remibrutinib— uncovered
APICAL_SURFACE0.160Temsirolimus— uncovered
ADIPOGENESIS0.158Inavolisib— uncovered
PEROXISOME0.150Idelalisib— uncovered
COMPLEMENT0.145Inavolisib— uncovered
APOPTOSIS0.131Idelalisib— uncovered
BILE_ACID_METABOLISM0.105Inavolisib— uncovered